PM54

Phase 1Small molecule

PPharmaMar

PM54 is one of 71 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsRecruiting

Advanced MalignanciesRecruiting

Advanced Solid TumorsPhase 1

Recruiting

Advanced MalignanciesPreclinical

Recruiting

Competition

Competitive Landscape

286 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

24 2

Tecentriq

Roche

Phase 2

11 3

Beyfortus

BeiGene

Phase 2

10 4

Taxotere

AAvyxa

Phase 2

23 5

Libtayo

Regeneron

Phase 2

3 6

Afinitor

Novartis

Phase 2

3 7

Alimta

SShawn Eagle

Phase 2

12 8

Myrbetriq

Astellas

Phase 2

1 9

Tarceva

OOSI Pharmaceuticals

Phase 2

6 10

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Advanced Solid Tumors

NCT05841563

Q2 2029

PreclinicalRecruiting

Advanced Malignancies

NCT07644039

Q4 2029

PreclinicalNot yet recruiting

Solid Tumor

NCT07839819

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

Recruiting·PPharmaMar·Phase 1·NCT05841563·125 enrolled

Advanced Malignancies1 trial

A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants Who Were Previously Treated for Advanced Malignancies

Recruiting·PPharmaMar·Preclinical·NCT07644039·119 enrolled

Solid Tumor1 trial

Phase 1/2 Master Study to Assess the Safety and Efficacy of PM54 in Combination With Cytotoxic and Targeted Agents for the Treatment of Advanced Solid Tumors

Not yet recruiting·PPharmaMar·Preclinical·NCT07839819·231 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PM54. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PM54 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PM54. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PharmaMar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPharmaMar

PM54

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2029

Q4 2029

Trials by Indication[1]

Advanced Solid Tumors1 trial

Advanced Malignancies1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News